Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:57:07.338Z.
Calculation as of: 2026-10-06T15:57:07.338Z.
Quote observation: 2026-10-06T15:55:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$264.23M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.73M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$268.68M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$268.85M
Price/FCF Ratio
N/A
TTM Avg
4.69
3Y Avg
5.94
5Y Avg
441.51
Market Cap
$269.10M
Price/FCF Ratio
N/A
TTM Avg
61.29
3Y Avg
61.29
5Y Avg
61.29
Market Cap
$257.66M
Price/FCF Ratio
458.48
TTM Avg
239.45
3Y Avg
256.85
5Y Avg
209.66
Market Cap
$274.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $264.23M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $268.68M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $268.85M | N/A | 4.69 | 5.94 | 441.51 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $269.10M | N/A | 61.29 | 61.29 | 61.29 |
| AC Immune S.A. (ACIU)vs › | $258.00M | N/A | 5.28 | 5.50 | 5.50 |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.66M | 458.48 | 239.45 | 256.85 | 209.66 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $252.22M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
